Ruling in a closely followed dispute over the biosimilar drug Zarxio, the U.S. Court of Appeals for the Federal Circuit did its best Tuesday to “unravel the riddle, solve the mystery, and comprehend the enigma” of the 2009 Biologics Price Competition and Innovation Act.
The result was three separate opinions ultimately providing a mixed bag of results for drugmakers engaged in bringing biosimilars to market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
